TMCnet News
RedPath Announces Publication of Study in Endoscopy Showing the Accuracy of PathFinderTG® in Managing Pancreatic CystsPITTSBURGH --(Business Wire)-- RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, announced that results from The National Pancreatic Cyst Registry, a multicenter clinical study, were published online in Endoscopy. The manuscript, titled, "Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts," can be accessed at https://www.thieme-connect.de/products/ejournals/html/10.1055/s-0034-1390742. The study concluded that integrated molecular pathology using PathFinderTG more accurately determines malignant potential of pancreatic cysts than current guideline-recommended criteria and, subsequently, can help guide patient management decisions for surgery and surveillance. These conclusions were drawn from a review of disease outcomes in 492 patients who had PathFinderTG testing as part of their standard of care when cytological analysis of cyst fluid was not definitive for the presence of malignancy. he results show that PathFinderTG is the most accurate, clinically validated test available for determining risk of malignancy in pancreatic cysts. PathFinderTG could distinguish patients who had 97% probability of benign disease at 3 years follow-up from those who were at 31-76 fold greater risk of malignancy. This is a marked improvement in risk stratification over that of current guideline-recommended criteria. "We are extremely pleased to have such positive data on our PathFinderTG test published," said Dennis M. Smith, Jr., M.D., president and chief executive officer of RedPath Integrated Pathology. "These results clearly demonstrate the importance of PathFinderTG when it comes to managing pancreatic cyst patients." About PathFinderTG RedPath's patented PathFinderTG Pancreas profile uses LOH markers, oncogene mutations, and DNA content abnormalities to evaluate pancreatic cystic lesions and integrate these analyses with clinical features to accurately risk stratify patients for the development of pancreatic adenocarcinoma. PathFinderTG has been demonstrated to be superior to standard first-line tests for risk stratification. All patients, except those with a malignant diagnosis on cytology, are ideal candidates for testing with PathFinderTG. About RedPath Integrated Pathology RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath's patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit www.redpathip.com or contact Andrew Mignatti at 412-224-6100. |
